Sarasin & Partners LLP Trims Stake in Amgen Inc. $AMGN

Sarasin & Partners LLP reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 48.4% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 343,948 shares of the medical research company’s stock after selling 322,502 shares during the quarter. Amgen accounts for about 1.5% of Sarasin & Partners LLP’s investment portfolio, making the stock its 24th largest position. Sarasin & Partners LLP’s holdings in Amgen were worth $124,550,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Emprise Bank bought a new position in shares of Amgen in the 2nd quarter worth $204,000. Evanson Financial LLC bought a new stake in shares of Amgen during the 2nd quarter worth $563,000. Foster Group Inc. grew its position in Amgen by 3.9% in the second quarter. Foster Group Inc. now owns 2,616 shares of the medical research company’s stock worth $947,000 after acquiring an additional 99 shares in the last quarter. JGP Wealth Management LLC increased its stake in Amgen by 2.3% in the second quarter. JGP Wealth Management LLC now owns 43,268 shares of the medical research company’s stock valued at $15,668,000 after acquiring an additional 975 shares during the last quarter. Finally, Mirador Capital Partners LP increased its stake in Amgen by 11.3% in the second quarter. Mirador Capital Partners LP now owns 1,410 shares of the medical research company’s stock valued at $511,000 after acquiring an additional 143 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 0.7%

AMGN opened at $404.85 on Friday. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $418.40. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 4.44. The business’s 50-day moving average price is $361.29 and its 200-day moving average price is $355.86. The company has a market cap of $218.50 billion, a P/E ratio of 25.16, a P/E/G ratio of 4.10 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the prior year, the business posted $6.02 EPS. Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts expect that Amgen Inc. will post 22.47 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is 70.15%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported second-quarter revenue of $10.05 billion, up approximately 9.5% year over year, while adjusted EPS of $6.29 exceeded the roughly $5.62 analyst consensus. Growth across cardiovascular, bone-health, and rare-disease medicines helped offset pressure from older products facing biosimilar competition. Amgen second-quarter sales rise 9%, profit tops Street view
• Positive Sentiment: Management raised its 2026 outlook, with adjusted EPS guidance of $22.30 to $23.50 and revenue guidance of approximately $38.2 billion to $39.4 billion. The update reflects momentum across Amgen’s portfolio and continued progress in its late-stage pipeline. AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
• Positive Sentiment: Several firms raised their targets following the results. UBS lifted its target to $440 and TD Cowen to $452, while BMO, Oppenheimer, and Scotiabank set targets near $450 or higher; UBS and TD Cowen maintained bullish ratings. Amgen Price Target Raised to $440 at UBS
• Neutral Sentiment: Analyst sentiment remains divided. Citi maintained a Hold rating, while UBS retained Buy; other firms raised targets but kept Hold, Equal Weight, or Underperform ratings, suggesting some analysts believe the upgraded outlook is already reflected in the valuation. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Amgen abandoned an obesity-drug candidate, while pressure from biosimilars and weaker performance in some legacy franchises remains a headwind. Questions surrounding Tavneos clinical data add regulatory and reputational uncertainty. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Negative Sentiment: A reported patient-data breach has prompted a law-firm investigation into potential privacy claims, creating additional legal, operational, and reputational risk for Amgen. Amgen Data Breach Class Action Investigation

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. The Goldman Sachs Group set a $389.00 target price on Amgen in a research report on Friday, June 5th. Guggenheim increased their price target on shares of Amgen from $340.00 to $343.00 and gave the company a “neutral” rating in a research report on Monday, July 13th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 price target on shares of Amgen in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $367.93.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.